In a phase 2 trial, treatment with sotatercept shows reduced pulmonary vascular resistance and heart outcomes in patients ...

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing ...

In a large trial, the approved therapy Winrevair showed confirmed benefits for CpcPH-HFpEF, a type of PH associated with ...

WASHINGTON -- The novel investigational therapy seralutinib effectively reduced pulmonary vascular resistance (PVR) in patients with pulmonary arterial hypertension (PAH) on standard background ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The classification of “responder” was earned by ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. A previous study found that seralutinib lowered ...

PAH therapies improved hemodynamic parameters and reduced NT-proBNP levels in PH-ILD patients, indicating potential benefits. Precision medicine could help identify PH-ILD patients who may benefit ...

"ACC 2026: Sotatercept shows signal in CpcPH-HFpEF at lower dose" was originally created and published by Pharmaceutical ...

Patients with pulmonary arterial hypertension (high blood pressure in the arteries that supply the lungs, also called PAH) had approximately double the reduction in pulmonary vascular resistance (PVR) ...

With the FDA expected this week to approve a first-in-class treatment from Merck for pulmonary arterial hypertension (PAH), Johnson & Johnson has beaten its New Jersey rival to the punch with a nod ...

Individualized treatment and close monitoring are essential for pregnant women with pulmonary hypertension due to high maternal and fetal risks. Prognosis in pulmonary hypertension varies with ...